Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system characterized by substantial clinical and pathological heterogeneity, ...

Tyruko, the first biosimilar of Tysabri, is now available in the U.S., providing a lower-cost treatment option for adults ...

Treatment with fenebrutinib in a 2-year open-label extension study led to significantly reduced disease-related inflammatory activity in those with relapsing MS, according to speaker at ECTRIMS ...

Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the ...

An insurance company repeatedly denied a Wisconsin woman coverage for a medication her doctor prescribed to treat her ...

Medical research is ultimately not just about curing disease — it’s about creating a healthier, longer and higher-quality life for everyone.

Explore the concept of the MS prodrome, a period with subtle symptoms before multiple sclerosis onset. Learn about early ...

Two-Year Clinical Trial with UCSF and Sutter Health Will Study Fixational Eye Movements as a Biomarker of MS Progression SANTA CLARA, CA / ACCESS Newswire / November 19, 2025 / C. Light Technologies, ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 27 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

Kemi Badenoch blasted Labour for allowing the asylum crisis to spiral out of control during Labour's first 16 months in ...